HTBA and Abolis Partner to Revolutionize Polyphenol Production

Web DeskMay 15, 2024 12:33 AMbusiness
  • Collaboration aims to create high-value molecules scarce in the market
  • Partnership drives innovation, enhances production efficiency, and reduces manufacturing costs
  • Strategic alliance signifies a promising future for polyphenol production and innovation
HTBA and Abolis Partner to Revolutionize Polyphenol ProductionImage Credits: prnewswire_apac
HealthTech Bioactives and Abolis collaborate to revolutionize polyphenol production, driving innovation and sustainability in the health sector.

HealthTech Bioactives (HTBA) has joined forces with Abolis to revolutionize the production of valuable polyphenols, essential compounds with numerous health benefits. HTBA, a leading global provider of health solutions, and Abolis Biotechnologies, a specialist in microbial strain development, are collaborating to overcome supply chain challenges and drive innovation in the industry.

The partnership between HTBA and Abolis aims to create high-value molecules that are currently scarce in the market. By leveraging Abolis' expertise in microbial strain development and HTBA's market knowledge, the collaboration seeks to enhance production efficiency and reduce manufacturing costs compared to traditional extraction methods.

Abolis CEO, Cyrille Pauthenier, expressed enthusiasm for the partnership, emphasizing the synergy between the companies' skills. This strategic alliance marks a significant step towards sustainable production methods for polyphenols, benefiting consumers and fostering industry growth.

HTBA CEO, Alexandre Valls-Coma, praised the partnership with Abolis, highlighting their shared values and commitment to delivering value to customers. The collaboration between these two companies signifies a promising future for polyphenol production and innovation in the health sector.

Abolis, a French company with over 40 years of experience, is dedicated to developing biotechnological solutions for various industries, promoting sustainability and quality across the value chain. HTBA, headquartered in Barcelona, Spain, focuses on providing innovative health solutions to meet market demands.

The partnership between HealthTech Bioactives and Abolis represents a significant advancement in the production of polyphenols, offering promising solutions for the health industry. By combining their expertise and resources, these companies are poised to drive innovation, enhance production efficiency, and deliver value to consumers. This collaboration underscores the importance of sustainable practices and technological advancements in meeting the evolving needs of the market.

Related Post